Disease workspace

Benign Prostatic Hyperplasia

Non-malignant prostate enlargement causing lower urinary tract symptoms.

Unmet need

Alternatives to surgery for moderate-to-severe LUTS.

Androgen signalingSmooth muscle proliferation

Evidence behind this

Confidence score95%

Signal strength: HighLevel 1 (RCT + regulatory approval)

Evidence grade

Approved

Reduced prostate volume, improved symptom scores vs placebo.

Mechanism

DHT reduction decreases prostate volume and improves urinary flow.

clinical trialfda labelPhase III

Authoritative sources

PubMed · 7688365
Finasteride in benign prostatic hyperplasia (PLESS)
McConnell JD et al. (1993)
View
ClinicalTrials.gov · NCT00021880
PLESS trial
View
FDA · 020180
Proscar (finasteride)
View

AI-generated summary

Generated March 15, 2026Last verified June 24, 2026

Finasteride is FDA-approved for BPH with Phase III PLESS trial evidence demonstrating symptom and volume benefits. 5α-reductase mechanism directly addresses disease pathophysiology.

Source papers

McConnell JD et al., NEJM 1993

This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.